The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer.
Melinda L. Telli
Consultant or Advisory Role - Sanofi (U)
Research Funding - Sanofi
Kristin C. Jensen
No relevant relationships to disclose
Allison W. Kurian
Research Funding - Sanofi
Shaveta Vinayak
No relevant relationships to disclose
Jafi A. Lipson
No relevant relationships to disclose
Elizabeth A. Schackmann
No relevant relationships to disclose
Irene Wapnir
No relevant relationships to disclose
Robert W. Carlson
Research Funding - Sanofi
Joseph A. Sparano
Consultant or Advisory Role - Sanofi
Bobbie Head
No relevant relationships to disclose
Lori J. Goldstein
Consultant or Advisory Role - Sanofi
Barbara B. Haley
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Judith Manola
Research Funding - Sanofi
James M. Ford
Research Funding - Sanofi